Top Stocks Soaring: How to Manage Your Winners

6 min read
1 views
Sep 8, 2025

Hot stocks like Carvana and eBay are soaring! But what's the next move? Uncover expert strategies to manage your winners and avoid pitfalls in this market...

Financial market analysis from 08/09/2025. Market conditions may have changed since publication.

Ever stared at your portfolio and felt that rush when a stock you picked starts climbing like a rocket? It’s thrilling, but it also brings that nagging question: What do I do now? Stocks like Carvana, eBay, and Alnylam Pharmaceuticals have been tearing up the charts lately, posting jaw-dropping gains. But as any seasoned investor knows, riding the wave of a hot stock isn’t just about basking in the glory—it’s about knowing when to hold, when to fold, or when to cash in. In my experience, the real skill lies in managing those winners without letting emotions or market noise derail your strategy.

Navigating the Highs of Winning Stocks

The stock market can feel like a wild ride, and when you’ve got stocks that are outperforming, it’s tempting to just sit back and enjoy. But here’s the thing: markets are unpredictable. A stock that’s soaring today could stumble tomorrow due to a downgrade, a broader market dip, or a shift in fundamentals. That’s why having a solid plan to manage your high-growth stocks is non-negotiable. Let’s dive into three standout performers—Alnylam Pharmaceuticals, eBay, and Carvana—and explore how to keep your portfolio thriving while dodging potential pitfalls.


Alnylam Pharmaceuticals: Riding the Biotech Boom

Biotech stocks can be a rollercoaster, but Alnylam Pharmaceuticals (ALNY) has been a standout. Since early June 2025, this stock has surged over 50%, driven by blockbuster financials and regulatory wins. The company reported a whopping 64% year-over-year revenue increase in Q2 2025, with net product revenues hitting $672 million. Their star drug, AMVUTTRA, raked in $544 million alone, prompting Alnylam to raise its full-year revenue forecast to as much as $2.8 billion. Add to that the European Commission’s approval of AMVUTTRA for ATTR cardiomyopathy, and you’ve got a stock with serious momentum.

Biotech is a high-risk, high-reward game, but when a company like Alnylam combines strong financials with regulatory success, it’s hard to ignore.

– Market analyst

So, what’s the play here? The stock is currently consolidating around the $450 level, which is a healthy sign after such a sharp run. The Relative Strength Index (RSI) is cooling off, suggesting room for another breakout. If you’re in, I’d stay long but keep an eye on the $400 mark. A sustained drop below that could signal a shift in sentiment, so consider it your gut-check moment. For those with a longer horizon, Alnylam’s pipeline—especially its hypertension drug zilebesiran, now in a massive Phase 3 trial—offers plenty of catalysts to watch through 2026.

  • Why it’s hot: Stellar Q2 earnings, regulatory approvals, and a robust pipeline.
  • Risk management tip: Set a stop-loss below $400 to protect gains.
  • Long-term play: Track clinical trial updates and reimbursement wins.

eBay: The E-Commerce Veteran’s Comeback

eBay might not be the shiny new kid on the block, but don’t sleep on it. Since May 2025, the stock has rocketed from just under $70 to over $100, a gain of more than 40%. What’s fueling this? A savvy pivot to AI-driven personalization, a focus on high-demand categories like trading cards and luxury goods, and a stellar Q2 performance. Revenue hit $2.73 billion, up 6% year-over-year, while earnings per share climbed 16% to $1.37, beating expectations. Gross Merchandise Volume (GMV) also grew to $19.5 billion, showing eBay’s still got game.

From a technical perspective, eBay’s chart is a trader’s dream. It’s been hugging its 50-day moving average like a lifeline, even shrugging off a hit from the closure of the de minimis loophole for tariff-free Chinese goods. If you’re trading, use that 50-day line (around $86) as a tight stop. For investors, watch how the stock behaves around the $82-$83 gap. An orderly pullback could be a buying opportunity, but a sloppy sell-off might mean it’s time to step back.

eBay’s reinvention shows that even legacy players can adapt and thrive in a competitive market.

– Financial commentator

Perhaps the most interesting aspect of eBay’s story is its ability to evolve. At 30 years old, it’s not just surviving—it’s thriving by leaning into trends like secondhand luxury and collectibles. Their Authenticity Guarantee program for luxury clothing is a masterstroke, building trust in a skeptical market. If you’re holding, this one’s worth riding, but stay disciplined with your exits.

StockEntry PointGain Since EntryRisk Level
Alnylam (ALNY)June 202550%Moderate
eBay (EBAY)May 202540%Low-Moderate
Carvana (CVNA)May 202525%High

Carvana: The High-Octane Turnaround

Carvana’s story is the stuff of Wall Street legend. Once teetering on the edge, this online car retailer has staged a comeback for the ages. Since May 2025, the stock has jumped over 25%, with Q2 2025 delivering its best-ever results: vehicle sales up 41% to 143,280 units, revenue soaring 42% to $4.84 billion, and a net income of $308 million. Adjusted EBITDA hit $601 million, and management raised full-year guidance to as much as $2.2 billion. That’s not just growth—that’s a full-on transformation.

But here’s the catch: Carvana is volatile. With a beta coefficient of 3.5, it’s more than three times as jumpy as the broader market. Its monthly standard deviation is a wild 130% (compared to the S&P 500’s 15%). The chart shows an intact uptrend, but a recent dip below the 50-day moving average gave investors a scare before bulls stepped in. If you’re in, I’d hold as long as the trend stays clean, but brace for the ride. This stock isn’t for the faint of heart.

Carvana’s turnaround proves that bold innovation and operational discipline can revive even the riskiest bets.

– Investment strategist

Carvana’s success hinges on its customer-centric innovations—think vending machines for cars and seamless home delivery. These aren’t just gimmicks; they’re driving profitability and investor confidence. If you’re tempted to jump in, just know you’re signing up for some serious ups and downs. Keep a stop-loss in mind and don’t get too attached.

  1. Monitor volatility: Use technical levels like the 50-day moving average to gauge momentum.
  2. Stay informed: Watch for updates on Carvana’s operational efficiencies and market share.
  3. Manage risk: Set clear exit points to avoid getting caught in a sharp pullback.

The Art of Risk Management

Winning stocks are exciting, but they don’t come with a guarantee. Markets shift, trends reverse, and what’s hot today can cool off fast. That’s why risk management is the backbone of any successful portfolio. Whether it’s setting stop-loss orders, watching key technical levels, or staying attuned to company fundamentals, discipline is what separates the pros from the amateurs. For Alnylam, eBay, and Carvana, the strategy is clear: ride the winners, but always have an exit plan.

Portfolio Success Formula:
  50% Picking Winners
  30% Risk Management
  20% Patience

One thing I’ve learned over the years is that no stock is a “set it and forget it” deal. Regularly check in on your positions. Are the fundamentals still strong? Is the chart showing signs of weakness? For Alnylam, keep tabs on clinical trial progress. For eBay, watch how it navigates e-commerce competition. For Carvana, stay alert for any cracks in its operational story. Being proactive keeps you ahead of the curve.


Why These Stocks Matter

Stocks like Alnylam, eBay, and Carvana aren’t just random picks—they’re snapshots of where the market’s energy is right now. Biotech is heating up with innovation, e-commerce is finding new ways to compete, and disruptive companies like Carvana are rewriting the rules. But as exciting as these stories are, they come with a catch: you’ve got to stay sharp. Markets don’t care about your feelings, and they won’t wait for you to figure out your next move.

So, what’s the takeaway? These stocks are winners, but they’re not invincible. Use technical levels like the 50-day moving average or key support zones to guide your decisions. Stay informed about company developments, and don’t be afraid to take profits if the trend turns. Investing is as much about protecting your capital as it is about chasing gains. Keep that balance, and you’ll be in a better spot to navigate whatever the market throws your way.

The market rewards those who plan, adapt, and act with discipline.

– Veteran investor

Got a winning stock in your portfolio? Drop a comment below and let us know how you’re managing it. These updates are all about keeping you in the loop, so if this format works for you, we’ll keep bringing it back with more insights on the market’s hottest names.

Cryptocurrencies are the first self-limiting monetary systems in the history of mankind, and nothing that comes from a government or a bank will ever be able to do that.
— Andreas Antonopoulos
Author

Steven Soarez passionately shares his financial expertise to help everyone better understand and master investing. Contact us for collaboration opportunities or sponsored article inquiries.

Related Articles